Dear PALLAS Participant:
On behalf of AFT, ABCSG, and Pfizer, we want to thank you sincerely for your participation in the PALbociclib CoLlaborative Adjuvant Study: A Randomized Phase III Trial of Palbociclib With Standard Adjuvant Endocrine Therapy Versus Standard Adjuvant Endocrine Therapy Alone for Hormone Receptor Positive (HR+) / Human Epidermal Growth Factor Receptor 2 (HER2)- Negative Early Breast Cancer (PALLAS).
Participants from all over the world are contributing to the PALLAS study. As of November 2018, enrollment is complete and we have enrolled 5796 participants. It is only with the help of volunteers like you that we are able to perform the essential research to investigate potential treatments and prevention methods for patients with breast cancer.
As of December 2019, most participants are in the treatment - or follow up Phase but once all participants have completed their participation in the clinical study, study records and test results will be analyzed and presented.
If at any time you wish to access a public record of the study, you may locate this information on https://clinicaltrials.gov/ct2/show/NCT02513394
Thank you very much again for your participation and your contribution to medicine and science!
PALLAS Study Team
You are not alone in your fight against breast cancer. There are a lot of resources available within your reach.
Alliance Foundation Trials (AFT): AFT is a research organization that develops and conducts cancer clinical trials, working closely with pharmaceutical partners, research collaborators, and the Alliance for Clinical Trials in Oncology scientific investigators and institutional member network.
Austrian Breast & Colorectal Cancer Study Group (ABCSG): The ABCSG is Austria’s biggest and best established academic research organization that conducts internationally respected clinical trials to investigate breast and colon cancer. More than 25,000 patients have participated in ABCSG trials since 1984.
Breast International Group (BIG): BIG is an international nonprofit organization for academic breast cancer research groups from around the world. BIG facilitates and accelerates breast cancer research at the international level by stimulating cooperation between its 56 member groups and other academic networks and collaborating with, while working independently from, the pharmaceutical industry. Linked to over 3000 hospitals, BIG is the largest international network dedicated solely to breast cancer.
Clinicaltrials.gov: This site is a service of the US National Institutes of Health. It is a registry and results database of publicly and privately supported clinical studies of human participants conducted around the world.
German Breast Group (GBG): GBG is the leading breast cancer study group in Germany, conducting clinical trials in the adjuvant, neoadjuvant, preventative, and palliative settings.
International Clinical Trials Registry Platform (ICTRP): The mission of the World Health Organization (WHO) ICTRP is to ensure that a complete view of research is accessible to all those involved in healthcare decision making. This will improve research transparency and ultimately strengthen the validity and value of the scientific evidence base.
National Surgical Adjuvant Breast and Bowel Project (NSABP): The NSABP Foundation is a not-for-profit academic research organization with a nearly 60-year history of conducting groundbreaking research studies in breast and colorectal cancer. Its goal is to improve outcomes for cancer patients via improved therapeutic and prevention modalities.
PrECOG: PrECOG is a research company that focuses on cancer clinical trials. In conjunction with industry partners, PrECOG develops clinical trials in all areas of oncology.